Gufic Biosciences (509079) Q2 25/26 earnings summary

Executive summary

• Focused execution in hospital injectables, women's health, aesthetics, and surgical platforms, with strong emphasis on critical care, fertility, and toxin portfolios.

• Achieved total revenue of ₹230.4 Cr in Q2 FY26, up from ₹204.2 Cr in Q2 FY25, and ₹457.3 Cr for H1 FY26, up from ₹407 Cr in H1 FY25.

• Standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025, were reviewed and approved by the Board and auditors, with no material misstatements identified.

• Indore facility commenced production in Oct 2024, targeting global regulatory standards and margin accretion by FY27.

• International business expanded with first EU marketing authorization and 24 new product/facility approvals across multiple regulated and emerging markets.

Financial highlights

• Q2 FY26 revenue was INR 2,300 million, up from INR 2,270 million in Q1 and up 12.8% year-over-year; H1 FY26 revenue up 12.4% year-over-year.

• EBITDA for Q2 FY26 was ₹37.9 Cr with a margin of 16.45%, compared to ₹38.7 Cr and 18.95% in Q2 FY25.

• PAT for Q2 FY26 stood at ₹14.9 Cr, down from ₹21.8 Cr in Q2 FY25; H1 FY26 PAT was ₹27 Cr versus ₹42.6 Cr in H1 FY25.

• Indore plant contributed all incremental revenue; Navsari capacity fully utilized.

• Standalone net profit for Q2 FY26 was ₹1,493.71 lakhs, compared to ₹1,207.33 lakhs in Q2 FY25; consolidated net profit was ₹1,682.40 lakhs.

Outlook and guidance

• Indore facility expected to reach EBITDA break-even by Q4 FY 2026 and margin-accretive from FY 2027.

• CMO business anticipated to pick up from Q3, with more clients transitioning to Indore.

• International business projected to grow 32-33% year-over-year, driven by new tenders and market entries.

• Strategic focus on expanding regulated market presence, scaling CMO, and launching new products in critical care, fertility, and aesthetics.

• The company expanded its international presence by investing in Gufic Ireland Limited during the quarter.